Table 3.
Outcomes.
| Variable | Entire cohort | 2008–2009 | 2010–2011 | 2012–2014 | |
|---|---|---|---|---|---|
| 30 day survival | 133 (90.5%) | 36 (92%) | 37 (94%) | 60 (94%) | 0.2 |
| 1 yr survival | 122 (83%) | 33 (85%) | 36 (90%) | 53 (82%) | 0.3 |
| 2 yr survival | 104 (71%) | 27 (69%) | 29 (73%) | 48 (75%) | 0.2 |
| Stroke | 7 (4.7%) | 3 (8%) | 2 (5%) | 2 (3%) | 0.4 |
| Vascular complications | 18 (12%) | 7 (17%) | 6 (15%) | 5 (8%) | 0.15 |
| Pacemaker | 20 (13.6%) | 6 (15%) | 7 (18%) | 7 (11%) | 0.5 |
| Ejection fraction | 50 ± 8 | 50 ± 8 | 51 ± 9 | 49 ± 8 | 0.4 |
| AR | 0.9 ± 0.7 | 1.1 ± 0.7 | 1.2 ± 0.8 | 0.8 ± 0.6 | 0.2 |
| MR | 1.0 ± 0.8 | 1.2 ± 0.8 | 1.1 ± 0.6 | 0.9 ± 0.6 | 0.6 |
| Improvement in creatinine | 9.2% | 8% | 9% | 10% | 0.2 |
Data is expressed as mean ± standard deviation or number of patients (%).
AR is Aortic Regurgitation; MR is Mitral Regurgitation; EF measured by Simpsons.
Average creatinine improvement by discharge.